These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35682697)

  • 1. Podocyte-Related Mechanisms Underlying Survival Benefit of Long-Term Angiotensin Receptor Blocker.
    Zhu X; Gao D; Albertazzi V; Zhong J; Ma LJ; Du L; Shyr Y; Kon V; Yang HC; Fogo AB
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis.
    Naito T; Ma LJ; Yang H; Zuo Y; Tang Y; Han JY; Kon V; Fogo AB
    Am J Physiol Renal Physiol; 2010 Mar; 298(3):F683-91. PubMed ID: 20042458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
    Matsushita K; Yang HC; Mysore MM; Zhong J; Shyr Y; Ma LJ; Fogo AB
    Lab Invest; 2016 Jun; 96(6):602-9. PubMed ID: 26999660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis.
    Takagi N; Tanizawa T; Kon V; Fogo AB; Ichikawa I; Ma J
    Nephron Extra; 2012 Jan; 2(1):17-26. PubMed ID: 22479265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Erythropoietin Amplifies Beneficial Effects of Angiotensin II Blockade on Glomerulosclerosis.
    Wang J; Matsushita K; Zhong J; Ma LJ; Yang HC; Fogo AB
    Lab Invest; 2023 Feb; 103(2):100015. PubMed ID: 37039147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
    Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
    Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
    Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
    Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
    Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
    Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
    Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway.
    Nijenhuis T; Sloan AJ; Hoenderop JG; Flesche J; van Goor H; Kistler AD; Bakker M; Bindels RJ; de Boer RA; Möller CC; Hamming I; Navis G; Wetzels JF; Berden JH; Reiser J; Faul C; van der Vlag J
    Am J Pathol; 2011 Oct; 179(4):1719-32. PubMed ID: 21839714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of existing glomerulosclerosis by inhibition of aldosterone.
    Aldigier JC; Kanjanbuch T; Ma LJ; Brown NJ; Fogo AB
    J Am Soc Nephrol; 2005 Nov; 16(11):3306-14. PubMed ID: 16192423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
    Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
    Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.